PriceTargets.com logo

Rapport Therapeutics - RAPP Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $35.00
  • Forecasted Upside: 249.30%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$10.02 As of 03/13/2025 05:00 PM ET
▲ +0.01 (0.10%)

This chart shows the closing price for RAPP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
JanFebMar$10.02Closing price on 03/13/25:
Get New Rapport Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RAPP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RAPP

Analyst Price Target is $35.00
▲ +249.30% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Rapport Therapeutics in the last 3 months. The average price target is $35.00, with a high forecast of $35.00 and a low forecast of $35.00. The average price target represents a 249.30% upside from the last price of $10.02.

This chart shows the closing price for RAPP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
7/249/2412/243/253/26$5$13$20$28$35Closing price on 03/13/25: $10.02High$35.00Average$35.00Low$35.00




Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Rapport Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/17/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/15/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/14/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/12/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/14/2025

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/2/2024TD CowenInitiated CoverageBuy
7/2/2024Jefferies Financial GroupInitiated CoverageBuy$35.00
7/2/2024Stifel NicolausInitiated CoverageBuy$35.00
(Data available from 3/14/2020 forward)

News Sentiment Rating

0.28 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/16/2024
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/15/2024
  • 7 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/15/2024
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/14/2024
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/14/2024
  • 4 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/13/2025
  • 5 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/12/2025
  • 0 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/14/2025

Current Sentiment

  • 0 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Rapport Therapeutics logo
Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.
Read More

Today's Range

Now: $10.02
Low: $9.67
High: $10.55

50 Day Range

MA: $13.72
Low: $7.15
High: $19.48

52 Week Range

Now: $10.02
Low: $6.43
High: $29.74

Volume

227,750 shs

Average Volume

166,430 shs

Market Capitalization

$366.49 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Rapport Therapeutics?

The following Wall Street research analysts have issued reports on Rapport Therapeutics in the last twelve months: Jefferies Financial Group Inc., Stifel Nicolaus, and TD Cowen.
View the latest analyst ratings for RAPP.

What is the current price target for Rapport Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Rapport Therapeutics in the last year. Their average twelve-month price target is $35.00, suggesting a possible upside of 249.3%. Stifel Nicolaus has the highest price target set, predicting RAPP will reach $35.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $35.00 for Rapport Therapeutics in the next year.
View the latest price targets for RAPP.

What is the current consensus analyst rating for Rapport Therapeutics?

Rapport Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RAPP will outperform the market and that investors should add to their positions of Rapport Therapeutics.
View the latest ratings for RAPP.

What other companies compete with Rapport Therapeutics?

Other companies that are similar to Rapport Therapeutics include Arvinas, Calliditas Therapeutics AB (publ), Structure Therapeutics, Spyre Therapeutics and Aurinia Pharmaceuticals. Learn More about companies similar to Rapport Therapeutics.

How do I contact Rapport Therapeutics' investor relations team?

The company's listed phone number is (857) 321-8020 and its investor relations email address is investors@rapportrx.com. The official website for Rapport Therapeutics is www.rapportrx.com. Learn More about contacing Rapport Therapeutics investor relations.